Search
Trofinetide
go.drugbank.com/drugs/DB06045ApprovedTrofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was appro...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsTapinarof
go.drugbank.com/drugs/DB06083ApprovedInvestigationalTapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. It is available as a topical cream to be applied to the affected area once daily. Tapiranof was first discovered as ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesCenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigationalCenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersSulfadimethoxine
go.drugbank.com/drugs/DB06150ApprovedVet approvedWithdrawnSulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, a...
Synonyms: 2,6-dimethoxy-4-(p-aminobenzenesulfonamido)pyrimidineCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsAtrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalAtrasentan is a novel, selective endothelin A receptor antagonist (SERA). In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsAlogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalAlogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes ...
Mixtures: INCRESINA PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalTapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake. Tapentadol was first approved by the FDA on November 20, 2008. The exten...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalEltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesVernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalVernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher he...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsNalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawnNalmefene, a 6-methylene analogue of naltrexone, is an opioid receptor antagonist. It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. In Europe, nalmefene ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates